Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 853 to 863 of 863 entries
Sorted by: Best Match Show Resources per page
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.

Nature

Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, Ramos V, Cipolla M, Mendoza P, Agudelo M, Bednarski E, DaSilva J, Shimeliovich I, Dizon J, Daga M, Millard KG, Turroja M, Schmidt F, Zhang F, Tanfous TB, Jankovic M, Oliveria TY, Gazumyan A, Caskey M, Bieniasz PD, Hatziioannou T, Nussenzweig MC.
PMID: 34619745
Nature. 2021 Dec;600(7889):517-522. doi: 10.1038/s41586-021-04060-7. Epub 2021 Oct 07.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found...

Cite
Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature. 2021;600(7889):517-522doi: 10.1038/s41586-021-04060-7.
Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., Bednarski, E., DaSilva, J., Shimeliovich, I., Dizon, J., Daga, M., Millard, K. G., Turroja, M., Schmidt, F., Zhang, F., Tanfous, T. B., Jankovic, M., Oliveria, T. Y., Gazumyan, A., Caskey, M., Bieniasz, P. D., Hatziioannou, T., & Nussenzweig, M. C. (2021). Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 600(7889), 517-522. https://doi.org/10.1038/s41586-021-04060-7
Cho, Alice, et al. "Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination." Nature vol. 600,7889 (2021): 517-522. doi: https://doi.org/10.1038/s41586-021-04060-7
Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, Ramos V, Cipolla M, Mendoza P, Agudelo M, Bednarski E, DaSilva J, Shimeliovich I, Dizon J, Daga M, Millard KG, Turroja M, Schmidt F, Zhang F, Tanfous TB, Jankovic M, Oliveria TY, Gazumyan A, Caskey M, Bieniasz PD, Hatziioannou T, Nussenzweig MC. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature. 2021 Dec;600(7889):517-522. doi: 10.1038/s41586-021-04060-7. Epub 2021 Oct 07. PMID: 34619745.
Copy Download .nbib Format: NLM
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.

Nature

Schmidt F, Weisblum Y, Rutkowska M, Poston D, DaSilva J, Zhang F, Bednarski E, Cho A, Schaefer-Babajew DJ, Gaebler C, Caskey M, Nussenzweig MC, Hatziioannou T, Bieniasz PD.
PMID: 34544114
Nature. 2021 Dec;600(7889):512-516. doi: 10.1038/s41586-021-04005-0. Epub 2021 Sep 20.

The number and variability of the neutralizing epitopes targeted by polyclonal antibodies in individuals who are SARS-CoV-2 convalescent and vaccinated are key determinants of neutralization breadth and the genetic barrier to viral escape

Cite
Schmidt F, Weisblum Y, Rutkowska M, et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature. 2021;600(7889):512-516doi: 10.1038/s41586-021-04005-0.
Schmidt, F., Weisblum, Y., Rutkowska, M., Poston, D., DaSilva, J., Zhang, F., Bednarski, E., Cho, A., Schaefer-Babajew, D. J., Gaebler, C., Caskey, M., Nussenzweig, M. C., Hatziioannou, T., & Bieniasz, P. D. (2021). High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature, 600(7889), 512-516. https://doi.org/10.1038/s41586-021-04005-0
Schmidt, Fabian, et al. "High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape." Nature vol. 600,7889 (2021): 512-516. doi: https://doi.org/10.1038/s41586-021-04005-0
Schmidt F, Weisblum Y, Rutkowska M, Poston D, DaSilva J, Zhang F, Bednarski E, Cho A, Schaefer-Babajew DJ, Gaebler C, Caskey M, Nussenzweig MC, Hatziioannou T, Bieniasz PD. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature. 2021 Dec;600(7889):512-516. doi: 10.1038/s41586-021-04005-0. Epub 2021 Sep 20. PMID: 34544114.
Copy Download .nbib Format: NLM
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.

Nature

Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, Ramos V, Cipolla M, Mendoza P, Agudelo M, Bednarski E, DaSilva J, Shimeliovich I, Dizon J, Daga M, Millard KG, Turroja M, Schmidt F, Zhang F, Tanfous TB, Jankovic M, Oliveria TY, Gazumyan A, Caskey M, Bieniasz PD, Hatziioannou T, Nussenzweig MC.
PMID: 34619745
Nature. 2021 Dec;600(7889):517-522. doi: 10.1038/s41586-021-04060-7. Epub 2021 Oct 07.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found...

Cite
Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature. 2021;600(7889):517-522doi: 10.1038/s41586-021-04060-7.
Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., Bednarski, E., DaSilva, J., Shimeliovich, I., Dizon, J., Daga, M., Millard, K. G., Turroja, M., Schmidt, F., Zhang, F., Tanfous, T. B., Jankovic, M., Oliveria, T. Y., Gazumyan, A., Caskey, M., Bieniasz, P. D., Hatziioannou, T., & Nussenzweig, M. C. (2021). Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 600(7889), 517-522. https://doi.org/10.1038/s41586-021-04060-7
Cho, Alice, et al. "Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination." Nature vol. 600,7889 (2021): 517-522. doi: https://doi.org/10.1038/s41586-021-04060-7
Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, Ramos V, Cipolla M, Mendoza P, Agudelo M, Bednarski E, DaSilva J, Shimeliovich I, Dizon J, Daga M, Millard KG, Turroja M, Schmidt F, Zhang F, Tanfous TB, Jankovic M, Oliveria TY, Gazumyan A, Caskey M, Bieniasz PD, Hatziioannou T, Nussenzweig MC. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature. 2021 Dec;600(7889):517-522. doi: 10.1038/s41586-021-04060-7. Epub 2021 Oct 07. PMID: 34619745.
Copy Download .nbib Format: NLM
Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing.

European journal of medical research

Fischer JC, Schmidt AG, Bölke E, Keitel V, Feldt T, Jensen B, Freise NF, Häussinger D, Schneider EM, Hermsen D, Kindgen-Milles D, Knoefel WT, Haussmann J, Tamaskovics B, Plettenberg C, Scheckenbach K, Corradini S, Rox J, Balz V, Maas K, Schmidt L, Grebe O, Ehrhardt A, Gerber PA, Peiper M, Buhren BA, Lichtenberg A, Rezazadeh A, Budach W, Matuschek C.
PMID: 34517930
Eur J Med Res. 2021 Sep 13;26(1):104. doi: 10.1186/s40001-021-00574-y.

No abstract available.

Cite
Fischer JC, Schmidt AG, Bölke E, et al. Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing. Eur J Med Res. 2021;26(1):104doi: 10.1186/s40001-021-00574-y.
Fischer, J. C., Schmidt, A. G., Bölke, E., Keitel, V., Feldt, T., Jensen, B., Freise, N. F., Häussinger, D., Schneider, E. M., Hermsen, D., Kindgen-Milles, D., Knoefel, W. T., Haussmann, J., Tamaskovics, B., Plettenberg, C., Scheckenbach, K., Corradini, S., Rox, J., Balz, V., Maas, K., Schmidt, L., Grebe, O., Ehrhardt, A., Gerber, P. A., Peiper, M., Buhren, B. A., Lichtenberg, A., Rezazadeh, A., Budach, W., & Matuschek, C. (2021). Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing. European journal of medical research, 26(1), 104. https://doi.org/10.1186/s40001-021-00574-y
Fischer, Johannes C, et al. "Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing." European journal of medical research vol. 26,1 (2021): 104. doi: https://doi.org/10.1186/s40001-021-00574-y
Fischer JC, Schmidt AG, Bölke E, Keitel V, Feldt T, Jensen B, Freise NF, Häussinger D, Schneider EM, Hermsen D, Kindgen-Milles D, Knoefel WT, Haussmann J, Tamaskovics B, Plettenberg C, Scheckenbach K, Corradini S, Rox J, Balz V, Maas K, Schmidt L, Grebe O, Ehrhardt A, Gerber PA, Peiper M, Buhren BA, Lichtenberg A, Rezazadeh A, Budach W, Matuschek C. Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing. Eur J Med Res. 2021 Sep 13;26(1):104. doi: 10.1186/s40001-021-00574-y. PMID: 34517930; PMCID: PMC8436013.
Copy Download .nbib Format: NLM
Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses.

Science immunology

Feldman J, Bals J, Altomare CG, St Denis K, Lam EC, Hauser BM, Ronsard L, Sangesland M, Moreno TB, Okonkwo V, Hartojo N, Balazs AB, Bajic G, Lingwood D, Schmidt AG.
PMID: 34648356
Sci Immunol. 2021 Dec 10;6(66):eabl5842. doi: 10.1126/sciimmunol.abl5842. Epub 2021 Dec 10.

[Figure: see text].

Cite
Feldman J, Bals J, Altomare CG, et al. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. Sci Immunol. 2021;6(66):eabl5842doi: 10.1126/sciimmunol.abl5842.
Feldman, J., Bals, J., Altomare, C. G., St Denis, K., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., Hartojo, N., Balazs, A. B., Bajic, G., Lingwood, D., & Schmidt, A. G. (2021). Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. Science immunology, 6(66), eabl5842. https://doi.org/10.1126/sciimmunol.abl5842
Feldman, Jared, et al. "Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses." Science immunology vol. 6,66 (2021): eabl5842. doi: https://doi.org/10.1126/sciimmunol.abl5842
Feldman J, Bals J, Altomare CG, St Denis K, Lam EC, Hauser BM, Ronsard L, Sangesland M, Moreno TB, Okonkwo V, Hartojo N, Balazs AB, Bajic G, Lingwood D, Schmidt AG. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. Sci Immunol. 2021 Dec 10;6(66):eabl5842. doi: 10.1126/sciimmunol.abl5842. Epub 2021 Dec 10. PMID: 34648356.
Copy Download .nbib Format: NLM
Acute total hip arthroplasty versus open reduction internal fixation for posterior wall acetabular fractures in middle-aged patients.

OTA international : the open access journal of orthopaedic trauma

MacCormick LM, Lin CA, Westberg JR, Schmidt AH, Templeman DC.
PMID: 33937650
OTA Int. 2019 Mar 12;2(1):e014. doi: 10.1097/OI9.0000000000000014. eCollection 2019 Mar.

INTRODUCTION: Open reduction internal fixation (ORIF) is the standard of care for displaced acetabular fractures, but the inability to achieve anatomic reduction, involvement of the posterior wall, articular impaction, and femoral head cartilaginous injury are known to lead to...

Cite
MacCormick LM, Lin CA, Westberg JR, et al. Acute total hip arthroplasty versus open reduction internal fixation for posterior wall acetabular fractures in middle-aged patients. OTA Int. 2019;2(1):e014doi: 10.1097/OI9.0000000000000014.
MacCormick, L. M., Lin, C. A., Westberg, J. R., Schmidt, A. H., & Templeman, D. C. (2019). Acute total hip arthroplasty versus open reduction internal fixation for posterior wall acetabular fractures in middle-aged patients. OTA international : the open access journal of orthopaedic trauma, 2(1), e014. https://doi.org/10.1097/OI9.0000000000000014
MacCormick, Lauren M, et al. "Acute total hip arthroplasty versus open reduction internal fixation for posterior wall acetabular fractures in middle-aged patients." OTA international : the open access journal of orthopaedic trauma vol. 2,1 (2019): e014. doi: https://doi.org/10.1097/OI9.0000000000000014
MacCormick LM, Lin CA, Westberg JR, Schmidt AH, Templeman DC. Acute total hip arthroplasty versus open reduction internal fixation for posterior wall acetabular fractures in middle-aged patients. OTA Int. 2019 Mar 12;2(1):e014. doi: 10.1097/OI9.0000000000000014. eCollection 2019 Mar. PMID: 33937650; PMCID: PMC7953701.
Copy Download .nbib Format: NLM
Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif.

bioRxiv : the preprint server for biology

Hauser BM, Sangesland M, Lam EC, Denis KJS, Feldman J, Yousif AS, Caradonna TM, Kannegieter T, Balazs AB, Lingwood D, Schmidt AG.
PMID: 33330872
bioRxiv. 2021 Jun 29; doi: 10.1101/2020.12.07.415216.

Effective countermeasures are needed against emerging coronaviruses of pandemic potential, similar to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Designing immunogens that elicit broadly neutralizing antibodies to conserved viral epitopes on the major surface glycoprotein, spike, such as the...

Cite
Hauser BM, Sangesland M, Lam EC, et al. Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif. bioRxiv. 2021;doi: 10.1101/2020.12.07.415216.
Hauser, B. M., Sangesland, M., Lam, E. C., Denis, K. J. S., Feldman, J., Yousif, A. S., Caradonna, T. M., Kannegieter, T., Balazs, A. B., Lingwood, D., & Schmidt, A. G. (2021). Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2020.12.07.415216
Hauser, Blake M, et al. "Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2020.12.07.415216
Hauser BM, Sangesland M, Lam EC, Denis KJS, Feldman J, Yousif AS, Caradonna TM, Kannegieter T, Balazs AB, Lingwood D, Schmidt AG. Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif. bioRxiv. 2021 Jun 29; doi: 10.1101/2020.12.07.415216. PMID: 33330872; PMCID: PMC7743097.
Copy Download .nbib Format: NLM
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.

eLife

Mast FD, Fridy PC, Ketaren NE, Wang J, Jacobs EY, Olivier JP, Sanyal T, Molloy KR, Schmidt F, Rutkowska M, Weisblum Y, Rich LM, Vanderwall ER, Dambrauskas N, Vigdorovich V, Keegan S, Jiler JB, Stein ME, Olinares PDB, Herlands L, Hatziioannou T, Sather DN, Debley JS, Fenyö D, Sali A, Bieniasz PD, Aitchison JD, Chait BT, Rout MP.
PMID: 34874007
Elife. 2021 Dec 07;10. doi: 10.7554/eLife.73027.

The emergence of SARS-CoV-2 variants threatens current vaccines and therapeutic antibodies and urgently demands powerful new therapeutics that can resist viral escape. We therefore generated a large nanobody repertoire to saturate the distinct and highly conserved available epitope space...

Cite
Mast FD, Fridy PC, Ketaren NE, et al. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. Elife. 2021;10doi: 10.7554/eLife.73027.
Mast, F. D., Fridy, P. C., Ketaren, N. E., Wang, J., Jacobs, E. Y., Olivier, J. P., Sanyal, T., Molloy, K. R., Schmidt, F., Rutkowska, M., Weisblum, Y., Rich, L. M., Vanderwall, E. R., Dambrauskas, N., Vigdorovich, V., Keegan, S., Jiler, J. B., Stein, M. E., Olinares, P. D. B., Herlands, L., Hatziioannou, T., Sather, D. N., Debley, J. S., Fenyö, D., Sali, A., Bieniasz, P. D., Aitchison, J. D., Chait, B. T., & Rout, M. P. (2021). Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. eLife, 10. https://doi.org/10.7554/eLife.73027
Mast, Fred D, et al. "Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape." eLife vol. 10 (2021). doi: https://doi.org/10.7554/eLife.73027
Mast FD, Fridy PC, Ketaren NE, Wang J, Jacobs EY, Olivier JP, Sanyal T, Molloy KR, Schmidt F, Rutkowska M, Weisblum Y, Rich LM, Vanderwall ER, Dambrauskas N, Vigdorovich V, Keegan S, Jiler JB, Stein ME, Olinares PDB, Herlands L, Hatziioannou T, Sather DN, Debley JS, Fenyö D, Sali A, Bieniasz PD, Aitchison JD, Chait BT, Rout MP. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. Elife. 2021 Dec 07;10. doi: 10.7554/eLife.73027. PMID: 34874007; PMCID: PMC8651292.
Copy Download .nbib Format: NLM
Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Kommoss FKF, Stichel D, Mora J, Esteller M, Jones DTW, Pfister SM, Brack E, Wachtel M, Bode PK, Sinn HP, Schmidt D, Mentzel T, Kommoss F, Sahm F, von Deimling A, Koelsche C.
PMID: 33846547
Mod Pathol. 2021 Aug;34(8):1558-1569. doi: 10.1038/s41379-021-00804-y. Epub 2021 Apr 12.

Embryonal rhabdomyosarcoma (ERMS) of the uterus has recently been shown to frequently harbor DICER1 mutations. Interestingly, only rare cases of extrauterine DICER1-associated ERMS, mostly located in the genitourinary tract, have been reported to date. Our goal was to study...

Cite
Kommoss FKF, Stichel D, Mora J, et al. Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. Mod Pathol. 2021;34(8):1558-1569doi: 10.1038/s41379-021-00804-y.
Kommoss, F. K. F., Stichel, D., Mora, J., Esteller, M., Jones, D. T. W., Pfister, S. M., Brack, E., Wachtel, M., Bode, P. K., Sinn, H. P., Schmidt, D., Mentzel, T., Kommoss, F., Sahm, F., von Deimling, A., & Koelsche, C. (2021). Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 34(8), 1558-1569. https://doi.org/10.1038/s41379-021-00804-y
Kommoss, Felix K F, et al. "Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 34,8 (2021): 1558-1569. doi: https://doi.org/10.1038/s41379-021-00804-y
Kommoss FKF, Stichel D, Mora J, Esteller M, Jones DTW, Pfister SM, Brack E, Wachtel M, Bode PK, Sinn HP, Schmidt D, Mentzel T, Kommoss F, Sahm F, von Deimling A, Koelsche C. Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. Mod Pathol. 2021 Aug;34(8):1558-1569. doi: 10.1038/s41379-021-00804-y. Epub 2021 Apr 12. PMID: 33846547; PMCID: PMC8295035.
Copy Download .nbib Format: NLM
Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals.

GMS hygiene and infection control

Nürnberger L, Schmidt D, Szumlanski T, Kirchhoff L, Ross B, Steinmann J, Rath PM.
PMID: 33796441
GMS Hyg Infect Control. 2021 Mar 17;16:Doc13. doi: 10.3205/dgkh000384. eCollection 2021.

No abstract available.

Cite
Nürnberger L, Schmidt D, Szumlanski T, et al. Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals. GMS Hyg Infect Control. 2021;16:Doc13doi: 10.3205/dgkh000384.
Nürnberger, L., Schmidt, D., Szumlanski, T., Kirchhoff, L., Ross, B., Steinmann, J., & Rath, P. M. (2021). Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals. GMS hygiene and infection control, 16Doc13. https://doi.org/10.3205/dgkh000384
Nürnberger, Laura, et al. "Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals." GMS hygiene and infection control vol. 16 (2021): Doc13. doi: https://doi.org/10.3205/dgkh000384
Nürnberger L, Schmidt D, Szumlanski T, Kirchhoff L, Ross B, Steinmann J, Rath PM. Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from two German hospitals. GMS Hyg Infect Control. 2021 Mar 17;16:Doc13. doi: 10.3205/dgkh000384. eCollection 2021. PMID: 33796441; PMCID: PMC7983015.
Copy Download .nbib Format: NLM
Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.

Multiple sclerosis (Houndmills, Basingstoke, England)

Theodorsdottir A, Debrabant B, Magyari M, Kant M, Rasmussen PV, Malmberg CF, Norberg IA, Hansen V, Bech D, Schmidt MF, Schreiber K, Frederiksen JL, Sellebjerg F, Illes Z.
PMID: 33779361
Mult Scler. 2021 Dec;27(14):2254-2266. doi: 10.1177/13524585211003291. Epub 2021 Mar 29.

OBJECTIVE: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark.METHODS: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related...

Cite
Theodorsdottir A, Debrabant B, Magyari M, et al. Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. Mult Scler. 2021;27(14):2254-2266doi: 10.1177/13524585211003291.
Theodorsdottir, A., Debrabant, B., Magyari, M., Kant, M., Rasmussen, P. V., Malmberg, C. F., Norberg, I. A., Hansen, V., Bech, D., Schmidt, M. F., Schreiber, K., Frederiksen, J. L., Sellebjerg, F., & Illes, Z. (2021). Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. Multiple sclerosis (Houndmills, Basingstoke, England), 27(14), 2254-2266. https://doi.org/10.1177/13524585211003291
Theodorsdottir, Asta, et al. "Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 27,14 (2021): 2254-2266. doi: https://doi.org/10.1177/13524585211003291
Theodorsdottir A, Debrabant B, Magyari M, Kant M, Rasmussen PV, Malmberg CF, Norberg IA, Hansen V, Bech D, Schmidt MF, Schreiber K, Frederiksen JL, Sellebjerg F, Illes Z. Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. Mult Scler. 2021 Dec;27(14):2254-2266. doi: 10.1177/13524585211003291. Epub 2021 Mar 29. PMID: 33779361.
Copy Download .nbib Format: NLM
Showing 853 to 863 of 863 entries